ReviewFrontiers in immunology2026
Advances in molecular innate immune regulation in the development and therapeutic strategies of allergic rhinitis vaccines.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis (AR) is an IgE-dependent, Th2 cell-mediated disorder that significantly impairs patients' quality of life. In recent years, molecular innate immune regulation has emerged as a pivotal area of research, especially focusing on the use of Toll-like receptor (TLR) agonists as adjuvants in allergen immunotherapy (AIT). TLRs, key components of the innate immune system, recognize pathogen-associated molecular patterns and activate dendritic cells, thereby modulating adaptive immune responses to promote anti-allergic immune deviation. This review provides a comprehensive overview of the role of TLRs in the development of AR vaccines, summarizing the progress made with various TLR agonists and their potential applications in AIT. Emphasis is placed on the immunoregulatory characteristics of these molecules and the current status of clinical trials, aiming to offer a theoretical foundation and research direction for the design of more effective and fast-acting therapeutic strategies for allergic rhinitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.